| Identification | Back Directory | [Name]
5-(2,4-dichlorophenyl)-1-(4-methylphenyl)-3a,6a-dihydrosprio[1H-furo[3,4-c]pyrrole-3,2'-(1'H)-indene]-1',3',4,6(2'H,3H,5H)-tetrone | [CAS]
459789-75-4 | [Synonyms]
5-(2,4-dichlorophenyl)-3-(4-methylphenyl)-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone
Spiro[1H-furo[3,4-c]pyrrole-1,2'-[2H]indene]-1',3',4,6(3H,5H)-tetrone, 5-(2,4-dichlorophenyl)-3a,6a-dihydro-3-(4-methylphenyl)-
5-(2,4-dichlorophenyl)-1-(4-methylphenyl)-3a,6a-dihydrosprio[1H-furo[3,4-c]pyrrole-3,2'-(1'H)-indene]-1',3',4,6(2'H,3H,5H)-tetrone | [Molecular Formula]
C27H17Cl2NO5 | [MOL File]
459789-75-4.mol | [Molecular Weight]
506.33 |
| Chemical Properties | Back Directory | [Boiling point ]
782.1±60.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [solubility ]
DMSO: 2 mg/mL, clear | [form ]
Solid | [pka]
-2.53±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.
ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1]. | [in vivo]
ML-T7 (10-50 mg/kg; Intraperitoneal injection; every 2 days, 10 times) inhibits the growth of tumor and prolongs survival of HCC mice, without adverse effects on mice body weight[1].
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].
| Animal Model: | 10-week-old mice with spontaneous orthotopic HCC[1] | | Dosage: | 10-50 mg/kg | | Administration: | Intraperitoneal injection (i.p.), every 2 days, 10 times | | Result: | Increased CD8+ T cells in both tumor and spleen.
Inhibited T cell exhaustion.
Promoted the function of CTLs, NK cells, and DCs. |
| Animal Model: | 10-week-old mice with orthotopic Akt/c-Myc HCC[1] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.), every 2 days, 10 times | | Result: | Indicated stronger antituomr activity when treated with ML-T7 and Nivolumab (HY-P9903A).
Rejuvenated NK cells by the combination therapy.
Inhibited the accumulation of MDSCs and Tregs. |
| [References]
[1] Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752. DOI:10.1126/scitranslmed.adg6752 |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
|